Sledge Jr. GW, et al. MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer. LBA6_PR. ESMO 2019. 28 sep.-1 okt. 2019, Barcelona, Spanje.
Adjuvant ipilimumab bij stadium III-melanoom
jan 2017 | Dermato-oncologie, Immuuntherapie